MagSense HER2 imaging is designed to help clinicians see what ultrasound might miss — highlighting cancerous nodes with targeted precision. Imagion Biosystems is now preparing for Phase II clinical trials evaluating the MagSense HER2 imaging agent — designed to help detect the spread of HER2-positive breast cancer to regional lymph nodes without the need for invasive biopsies.
MagSense PSMA imaging utilizes the same PSMA-specific targeting molecule as PET tracers but without the need for radiation, enabling MRI to non-invasively detect prostate cancer and guide precision biopsies.
CATEGORY
